Balance Sheet Components

9 Months Ended

Sep. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BALANCE SHEET COMPONENTS

Inventory

Inventory consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Finished goods	$	2,871	$	1,702
Work in progress	2,806		2,936
Raw materials	13,123		5,374
Total inventory	$	18,800	$	10,012

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Clinical studies	$	9,632	$	6,733
Short-term lease liability	3,822		2,033
Deferred revenue	3,409		3,530
Professional fees	2,980		1,529
Deferred payments for intangible assets	2,000		2,000
Capital expenditures	1,648		—
Accrued royalty	1,598		1,072
Test sample processing fees	1,295		416
Contingent consideration	642		738
Other accrued expenses	3,573		2,551
Total accrued and other liabilities	$	30,599	$	20,602

CMS Accelerated and Advance Payment Program for Medicare Providers

On March 27, 2020, the U.S. government enacted the CARES Act. Pursuant to the CARES Act, CMS expanded its Accelerated and Advance Payment Program in order to increase cash flow to providers of services and suppliers impacted by the COVID-19 pandemic. CMS was authorized to provide accelerated or advance payments during the period of the public health emergency to any Medicare provider who submitted a request to the appropriate Medicare Administrative Contractor and met the required qualifications. During April 2020, the Company received an advance payment from CMS of approximately $20.5 million and recorded the payment as Deferred revenue - CMS advance payment on the Company's condensed consolidated balance sheet.

During December 2020, the Company reassessed the Deferred revenue - CMS advance payment and repaid the entire amount in January 2021. The Company recorded the amount as Refund liability - CMS advance payment on the condensed consolidated balance sheet as of December 31, 2020.